Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

European Journal of Cancer

Volumn 49, Issue 8, 2013, Pages 1815-1824

  Soria, Jean Charles ^a   Baselga, José ^b   Hanna, Nasser ^c   Laurie, Scott A ^d   Bahleda, Rastislav ^a   Felip, Enriqueta ^b   Calvo, Emiliano ^e   Armand, Jean Pierre ^f   Shepherd, Frances A ^g   Harbison, Christopher T ^h   Berman, David ^h   Park, Jong Soon ^h   Zhang, Steven ^h   Vakkalagadda, Blisse ^h   Kurland, John F ^h   Pathak, Ashutosh K ^h   Herbst, Roy S ⁱ  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e START Madrid Centro Integral Oncológico Clara Campal   (Spain)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g UNIVERSITY OF TORONTO   (Canada)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ YALE CANCER CENTER   (United States)

Author keywords

Pan HER VEGFR inhibitor; Phase I II; Solid tumours

Indexed keywords

ANGIOGENESIS INHIBITOR; BMS 690514; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ACNE; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER INHIBITION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DISEASE CONTROL; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRY SKIN; EPISTAXIS; EYE DISEASE; FATIGUE; HUMAN; HYPERTENSION; INFECTION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MEDIASTINUM DISEASE; NAUSEA; NEUROLOGIC DISEASE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; RHINITIS; SIDE EFFECT; THORAX DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; URINALYSIS; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EXANTHEMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84876671596     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.012     Document Type: Article

References (42)

1. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
2. N. Ferrara Role of vascular endothelial growth factor in the regulation of angiogenesis Kidney Int 56 1999 794 814
3. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
4. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
5. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
6. M. Reck, J. von Pawel, and P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
7. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
8. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
9. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
10. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
11. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
12. F.A. Shepherd, P.J. Rodrigues, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
13. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158
14. C.E. Geyer, J. Forster, and D. Lindquist Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743
15. R.S. Herbst, Y. Sun, and W.E. Eberhardt Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial Lancet Oncol 11 2010 619 626
16. F. Ciardiello, R. Bianco, and V. Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
17. R.M. Shaheen, S.A. Ahmad, and W. Liu Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors Br J Cancer 85 2001 584 589
18. Y.D. Jung, P.F. Mansfield, and M. Akagi Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model Eur J Cancer 38 2002 1133 1140
19. C.H. Baker, C.C. Solorzano, and I.J. Fidler Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer Cancer Res 62 2002 1996 2003
20. S.R. Wedge, D.J. Ogilvie, and M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
21. K. Yokoi, P.H. Thaker, and S. Yazici Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model Cancer Res 65 2005 3716 3725
22. Y.W. Park, M.N. Younes, and S.A. Jasser AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice Clin Cancer Res 11 2005 1963 1973
23. M. Gutierrez, and G. Giaccone Antiangiogenic therapy in nonsmall cell lung cancer Curr Opin Oncol 20 2008 176 182
24. M. Reck, and L. Crino Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer Lung cancer 63 2009 1 9
25. R.S. Herbst, R. Ansari, and F. Bustin Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial Lancet 377 2011 1846 1854
26. R. Bahleda, J. Soria, and C. Harbison Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514 J Clin Oncol 27 Suppl. 2009 [abstr. 8089]
27. T. Wong, M. Ayers, and S. Emanuel Inhibition of EGFR/HER2 signaling in tumor cells and VEGFR2 activity in tumor endothelium contribute to the preclinical anti-tumor activity of BMS-690514 AACR Meeting Abstr 2007 [abstr. 4007]
28. T. de La Motte Rouge, L. Galluzzi, and K.A. Olaussen A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib Cancer Res 67 2007 6253 6262
29. L.J. Christopher, H. Hong, and B. Vakkalagadda Metabolism and disposition of [14C]BMS-690514 ((3R,4R)-4-amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1- f][1,2,4]triazin-5-yl)methyl)-3-piperidinol), an ErbB/VEGFR inhibitor, after oral administration to humans Drug Metab Dispos 38 2010 2049 2059
30. J. Baselga, J. Albanell, and A. Ruiz Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 2005 5323 5333
31. F.R. Hirsch, M. Varella-Garcia, and J. McCoy Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 23 2005 6838 6845
32. V.L. Keedy, and A.B. Sandler Inhibition of angiogenesis in the treatment of non-small cell lung cancer Cancer Sci 98 2007 1825 1830
33. J.M. Roodhart, M.H. Langenberg, and E. Witteveen The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol 3 2008 132 143
34. H. Izzedine, S. Ederhy, and F. Goldwasser Management of hypertension in angiogenesis inhibitor-treated patients Ann Oncol 20 2009 807 815
35. A. Harandi, A.S. Zaidi, and A.M. Stocker Clinical efficacy and toxicity of Anti-EGFR therapy in common cancers J Oncol 2009 2009 567486 (14 pages)
36. H. Izzedine, O. Rixe, and B. Billemont Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension Am J Kidney Dis 50 2007 203 218
37. V. Guarneri, D.J. Lenihan, and V. Valero Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience J Clin Oncol 24 2006 4107 4115
38. M. Azizi, A. Chedid, and S. Oudard Home blood-pressure monitoring in patients receiving sunitinib N Engl J Med 358 2008 95 97
39. X. Zhu, K. Stergiopoulos, and S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 2009 9 17
40. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 26 2008 5204 5212
41. R. Bahleda, C. Massard, and J.C. Soria Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial Invest New Drugs 28 2010 350 352
42. Vakkalagadda B, Park JS, Ahlers CM, et al. Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects. J Clin Pharmacol 2011. [epub ahead of print].